Oncology Genetic Testing: Pharmacists’ Knowledge Gap

VBCC - July 2012, Volume 3, No 5 - AMCP Annual Meeting

San Francisco, CA—Knowledge of pharmacogenomics—the genomic factors contributing to individual variability in response to drug therapy (or personalized medicine)—enhances the ability to diagnose, prevent, and treat disease, especially a variety of cancers. The correct application of pharmacogenomics to patient management is essential for providing cost-effective care, but many providers, includ - ing physicians and pharmacists, are lacking appropriate knowledge of the science. Other barriers include lack of transparency in clinical utility and in appropriate reimbursement strategies.

At the 2012 Academy of Managed Care Pharmacy annual meeting, Angela Luong, PharmD, and colleagues at OPTUMInsight described the results of their survey of pharmacists regarding their knowledge of genetic testing and utilization strategies.

A total of 19 pharmacists at 4 different managed care organizations responded to the survey; their responses revealed a basic lack of knowledge of pharmacogenomics. The majority (84%) of respondents agreed or strongly agreed that pharmacogenomics will have an impact on healthcare expenditures and pharmacists should have a good knowledge base of related drug therapies and tests; however, they admitted they did not have much education in this area. Overall, 95% of participants scored <60% on a pharmacogenomics test.

In addition, knowledge of pharmacogenomics does not appear to immediately have a direct impact on patient care or benefit design. Only 47% of respondents said their plan requires prior authorization (PA) for the use of the US Food and Drug Administration–approved companion diagnostic test for vemurafenib compared with 58% of respondents whose plans require a PA for the companion test for crizotinib.

By contrast, only 16% of respondents said their plans require testing for HER2 mutation before prescribing trastuzumab compared with 58% of respondents whose plans do not require testing and 26% (n = 5) who did not know whether their plans require such testing.

Furthermore, the majority of respondents did not know whether their plans had reimbursement policies related to pharmacogenomics. Overall, this survey reveals gaps in pharmacists’ knowledge of personalized medicine utility and its relation to benefit design strategies.

Related Items
Vemurafenib Does Not Impact Health Plan Budget
Caroline Helwick
VBCC - July 2012, Volume 3, No 5 published on July 18, 2012 in AMCP Annual Meeting
Does CMS’s Coverage Decision for Sipuleucel-T Herald More Restrictive Policy?
VBCC - July 2012, Volume 3, No 5 published on July 18, 2012 in AMCP Annual Meeting
In Colorectal Cancer, Treatment Efficacy Is High Among the Elderly
Caroline Helwick
VBCC - July 2012, Volume 3, No 5 published on July 18, 2012 in AMCP Annual Meeting
Is Pemetrexed/Platinum Therapy Cost-Effective in NSCLC?
Audrey Andrews
VBCC - July 2012, Volume 3, No 5 published on July 18, 2012 in AMCP Annual Meeting
Variant Methodology Impedes Cost-effectiveness Research
VBCC - June 2010, Volume 1, No 2 published on June 17, 2010 in AMCP Annual Meeting
Managed Care Pharmacist Boosts Drug Replacement, Reimbursement
VBCC - June 2010, Volume 1, No 2 published on June 17, 2010 in AMCP Annual Meeting
Patients More Likely to Abandon Drug Therapy When Paying More Out of Pocket
VBCC - June 2010, Volume 1, No 2 published on June 17, 2010 in AMCP Annual Meeting
Survey Provides a Window Into Payers’ Decision-Making Process
VBCC - June 2010, Volume 1, No 2 published on June 17, 2010 in AMCP Annual Meeting
Researchers Analyze Relationship Between Pharmacogenomics and Appropriate Oncology Care
VBCC - June 2010, Volume 1, No 2 published on June 17, 2010 in AMCP Annual Meeting
Pemetrexed as Maintenance Therapy Likely to Have ‘Minimal Impact’ on Health Plan Budget
VBCC - June 2010, Volume 1, No 2 published on June 17, 2010 in AMCP Annual Meeting
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology